Will Diabetes Treatment Change with "One Injection"?—The Hope and Reality Reflected by KRIYA-839

A research study is currently drawing significant attention regarding the future of diabetes treatment.
This is the gene therapy candidate "KRIYA-839" being developed by Kriya Therapeutics.

Reports have introduced it as a potential treatment that could replace lifelong insulin injections with just one injection. If realized, this would not only improve convenience for type 1 diabetes treatment but could also transform the daily routine of constantly monitoring blood glucose levels and adjusting insulin doses according to diet, exercise, health, sleep, and stress.

However, there is something important to emphasize at the outset.
KRIYA-839 is not currently a treatment available to the public. It is not at a stage where it can be definitively said to "cure" diabetes. It is in the early stages of research, where safety and efficacy in humans will be carefully verified.

Despite this, the news is garnering significant interest because the treatment concept fundamentally differs from traditional diabetes management.

The Concept of Transforming Muscle into an "Insulin Production Site"

Type 1 diabetes is a disease where the pancreas's β-cells are destroyed due to immune abnormalities, leading to insufficient insulin production in the body. Insulin is an essential hormone for allowing glucose in the blood to be absorbed by cells, and its deficiency results in persistently high blood glucose levels.

Therefore, patients with type 1 diabetes continue daily blood glucose management by combining insulin injections, insulin pumps, and continuous glucose monitors. Recent technological advancements, such as closed-loop systems, have made management easier than before. However, blood glucose levels still fluctuate significantly due to dietary carbohydrate intake, exercise, illness, hormonal changes, and other factors.

KRIYA-839 aims not to fully restore the lost pancreatic function but to assign a new role to muscle cells.

This treatment uses a viral vector called AAV to deliver two pieces of genetic information to muscle cells. One is information for producing insulin, and the other is information related to glucokinase, which is crucial for responding to changes in blood glucose levels.

Glucokinase acts like a blood glucose sensor. It does not work excessively when blood glucose is low but responds when blood glucose rises. By incorporating this mechanism into muscle cells, insulin production may be adjusted according to the state of blood glucose, rather than continuously releasing insulin.

This is a crucial point.
In diabetes treatment, the lack of insulin is a problem, but inappropriate amounts and timing of insulin release also pose significant risks. If insulin is too effective, it can lead to hypoglycemia, which in severe cases can cause unconsciousness or life-threatening situations. Therefore, what is required of new treatments is not just the ability to "produce insulin," but to "work only as much as needed, when needed."

KRIYA-839 is attempting to tackle this challenge through gene therapy.

A Treatment That Delivers Genetic Information, Not Gene Editing

When people hear about gene therapy, they might worry, "Isn't it rewriting my DNA?" However, KRIYA-839 is described as a different approach from gene editing like CRISPR, which directly cuts or rewrites DNA.

The vector used is AAV, or adeno-associated virus, which serves as a "carrier" to deliver the desired genetic information to cells. This technology is already used in gene therapy for some rare diseases and is one of the essential foundational technologies in the field of gene therapy.

Of course, using AAV does not simply mean it is safe. There is a possibility that the body may mount an immune response to the vector, and it is necessary to carefully confirm the dosage, administration site, duration of expression, and any unexpected side effects. In the upcoming clinical trial, participants are expected to be given medication to temporarily suppress immune responses.

Thus, while the possibility of not requiring lifelong immunosuppression is attractive, it does not mean that considerations regarding immunity are unnecessary. This distinction is crucial when reading reports.

Promising in Animal Experiments, but Results in Humans Are Yet to Come

For KRIYA-839, the effect of lowering blood glucose has been confirmed in animal experiments, with some reports of long-lasting effects after a single treatment. This indeed raises expectations.

However, in medical research, there is a significant gap between "success in animals" and "safe and effective use in humans." Especially for type 1 diabetes, which involves complex interactions of immunity, metabolism, lifestyle, and blood glucose fluctuations, it cannot be evaluated solely based on short-term blood glucose improvement.

The upcoming PROGRESS trial is expected to evaluate the safety and efficacy of KRIYA-839 in adults with type 1 diabetes. The target group is described as adult patients with HbA1c above a certain level who are using closed-loop technology. This suggests an intention to target individuals whose blood glucose management status is relatively easy to monitor in this initial clinical trial.

The primary purpose of the initial trial is to first confirm safety.
Will blood glucose control truly improve? Can insulin doses be reduced? Will hypoglycemia not increase? How long will the effects last? Will immune responses not be an issue? Answering these questions will take time.

Therefore, it is premature to definitively say that "insulin injections will no longer be necessary" at this stage. More accurately, it should be expressed as "a treatment candidate that could significantly reduce the burden of insulin therapy is moving towards verification in humans."

The Growing Global Diabetes Burden and the Weight of Treatment

Diabetes is one of the diseases with a continuously increasing number of patients worldwide. Reports suggest that approximately 589 million people globally are living with diabetes. Including not only type 1 diabetes but also type 2 diabetes, gestational diabetes, and other types, its impact extends to healthcare costs, labor productivity, family caregiving burdens, and complications management.

The difficulty of diabetes treatment is not just in taking medication or administering injections.
Patients must constantly monitor their body's condition. If blood glucose is too high, the risk of future complications increases, while if it's too low, immediate danger arises. Before eating, before exercising, before sleeping, on days of illness, on days out, on travel days, on busy workdays—blood glucose is a constant concern in all these situations.

This "endless management" is a significant psychological burden for diabetes patients.

That's why the news of "a treatment that might have long-lasting effects with just one treatment" is not just a medical topic but is received as hope that affects life itself.

Mixed Expectations and Fatigue on Social Media

 

On social media, there are voices of expectation for new diabetes treatments like KRIYA-839, but cautious reactions are also prominent.

On LinkedIn, posts from experts involved in diabetes healthcare and those close to patient support highlight the potential of gene therapy to change the landscape of type 1 diabetes treatment. Particularly, the aim for long-term blood glucose improvement with a single treatment and the potential to avoid chronic immunosuppression are discussed as attractions distinct from traditional cell transplantation therapies.

On the other hand, on Reddit's type 1 diabetes community, reactions are more from the perspective of daily life.
There are tired voices saying, "We've been told a cure is five years away for decades." Some share experiences of being told as children that "a cure is coming soon," only to continue managing diabetes into adulthood.

These voices are not a rejection of research. Rather, they reflect the reality of patients who have repeatedly heard "groundbreaking" and "soon" but have not seen changes in their daily lives.
While scientific news can provide hope, excessive expressions can also hurt patients.

In some communities, opinions emphasize that "having a treatment" and "having access to it" are separate issues. This is a very important point. Even if KRIYA-839 is approved in the future, it will not become a treatment accessible to many unless conditions such as price, insurance coverage, target patients, implementation facilities, and long-term safety data are met.

"Having a treatment" is not enough.
It needs to be "safe, accessible, and available to those who need it."

The Weight of the Word "Cure"

In news about diabetes treatment, words like "cure," "complete recovery," and "freedom from lifelong injections" tend to be used. However, these words need to be handled carefully.

For patients with type 1 diabetes, the word "cure" is not just a medical term. It is directly connected to life, future, family, work, diet, sleep, and peace of mind. Therefore, it is necessary to balance conveying hope with accurately communicating reality.

What KRIYA-839 aims for is currently considered a concept close to "functional cure." In other words, it does not completely eliminate the cause of the disease but creates a state where blood glucose can be controlled more naturally, significantly reducing the burden of insulin therapy.

If in the future, some patients no longer need insulin injections, it would be a tremendous achievement. However, it does not guarantee the same effect for all patients. The effect may weaken in a few years, and additional treatments may be necessary. If there are elements that cannot be reversed after administration, evaluating those risks is also important.

Therefore, the appropriate perspective at this point is this.
KRIYA-839 has the potential to significantly change the future of type 1 diabetes treatment. However, it is still a possibility that needs to be verified, and it will only become realistic with clinical data.

New Possibilities for Existing Drugs

The report also touches on new research related to existing diabetes drugs, not just gene therapy. For example, studies have reported that GLP-1 receptor agonists and SGLT2 inhibitors are associated with a reduced risk of Alzheimer's disease and related dementias in patients with type 2 diabetes.

Additionally, research is underway to investigate the association of GLP-1 receptor agonists with cardiovascular and kidney risks in patients with type 1 diabetes. Traditionally, diabetes drugs have often been discussed as medications that lower blood glucose levels. However, they are now being evaluated for their effects on the heart, kidneys, brain, weight, inflammation, and overall metabolism.

This indicates a change in how the disease of diabetes is perceived.
The focus is shifting from merely looking at blood glucose levels to preventing complications, preserving quality of life, and extending long-term healthy life expectancy.

Gene therapies like KRIYA-839 are part of this trend. It is not just about temporarily lowering blood glucose levels, but about how much they can reduce the treatment burden on patients and how safely and long they can maintain effectiveness.

Points to Expect and Challenges Yet to Be Seen

The points to expect about KRIYA-839 are clear.

First, it has the potential to significantly reduce the treatment burden.
The possibility of being freed from daily injections, pump management, and frequent adjustments is very significant for patients.

Second, the idea of utilizing muscle cells has practical advantages.
Muscles are abundant in the body, have rich blood flow, and are easy to target for treatment. The idea of having another tissue take on insulin production, rather than regenerating the pancreas itself, is also interesting from an implementation perspective.

Third, it may avoid chronic immunosuppression.
In cell transplantation or islet transplantation, drugs to suppress immune rejection are a major issue. If KRIYA-839 can maintain effectiveness without long-term immunosuppression, it would be a significant differentiating point.

On the other hand, there are many challenges.

How long will the effect last?
Will the effect be too strong and cause hypoglycemia?
How will immune responses to AAV be managed?
Is re-administration possible?
Can it be used in children?
What will the price be?
Can it be widely used within the insurance system?
Will it be applicable to patients who already have good blood glucose management?
Is there any problem with continuously producing insulin in muscle cells in the long term?

These are questions that should be confirmed one by one in future clinical trials.

Patients Are Not Just Looking for "Dreams"

Looking at the reactions on social media, it becomes clear that what patients and families are seeking is not just simple dreams.
Many people welcome the progress of research. However, they are also tired of being overly hyped.

The hope that "it might be cured someday" is important.
But "how to continue living safely, stably, and with dignity now" is just as important.

In some patient communities, voices are calling for affordable insulin, user-friendly continuous glucose monitors, devices with fewer skin issues, and smarter pump systems, rather than news about treatment methods. This shows that cutting-edge treatment is not the only hope for patients.

Future treatments and current care.
Both are necessary.

The Conclusion We Can Draw Now

KRIYA-839 is a very important study in considering the future of diabetes treatment.
The idea of giving muscle cells the function of insulin production and blood glucose sensing steps beyond the traditional treatment of "supplementing insulin from outside."

If safety and efficacy are confirmed in humans, the lives of type 1 diabetes patients may change significantly. The burden of daily injections, fine-tuning, and anxiety about blood glucose fluctuations may be alleviated, potentially allowing patients to regain the attention and time taken by the disease.

However, that future is not yet guaranteed.
What is needed now is neither excessive optimism nor cynical denial. It is a stance of watching the results of clinical trials calmly while holding scientific expectations.

Diabetes research is undoubtedly moving forward.
Whether that progress reaches the point of truly changing patients' daily lives, KRIYA-839 is a new step towards answering that question.

---

Source URL

ad-hoc-news. Articles reporting on KRIYA-839, diabetes gene therapy, related diabetes drug research, diagnostic technology, and more.
https://www.ad-hoc-news.de/wissenschaft/di